A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Public ClinicalTrials.gov record NCT07020533. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Trial of CMV-MVA Triplex Vaccine in Haploidentical Stem Cell Donors and Recipients to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients of Hematopoietic Stem Cell Transplant
Study identification
- NCT ID
- NCT07020533
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- City of Hope Medical Center
- Other
- Enrollment
- 46 participants
Conditions and interventions
Conditions
- Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Hematopoietic and Lymphatic System Neoplasm
- Hodgkin Lymphoma
- Lymphoblastic Lymphoma
- Myelodysplastic Syndrome
- Myelofibrosis
- Myeloproliferative Neoplasm
- Non-Hodgkin Lymphoma
Interventions
- Biospecimen Collection Procedure
- Electronic Health Record Review Other
- Haploidentical Hematopoietic Cell Transplantation Procedure
- Letermovir Drug
- Multi-peptide CMV-Modified Vaccinia Ankara Vaccine Biological
- Myeloablative Conditioning Procedure
- Pheresis Procedure
- Recombinant Granulocyte Colony-Stimulating Factor Biological
Procedure · Other · Drug + 1 more
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 7, 2026
- Primary completion
- Feb 13, 2030
- Completion
- Feb 13, 2030
- Last update posted
- Mar 26, 2026
2026 – 2030
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | Recruiting |
| Northside Hospital | Atlanta | Georgia | 30342 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07020533, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07020533 live on ClinicalTrials.gov.